We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

High-Sensitivity Cardiac Troponin T Identifies Myocardial Injury with COVID-19

By LabMedica International staff writers
Posted on 01 Sep 2021
Print article
Image: The Automated Elecsys Troponin T Gen 5 STAT assay facilitates the diagnosis of myocardial infarction, also in patients with COVID-19 (Photo courtesy of Roche Diagnostics)
Image: The Automated Elecsys Troponin T Gen 5 STAT assay facilitates the diagnosis of myocardial infarction, also in patients with COVID-19 (Photo courtesy of Roche Diagnostics)
Cardiac troponin (cTn) is the preferred biomarker for the detection of myocardial injury (MI), which is defined when there is at least one cTn concentration above the 99th percentile upper-reference limit (URL) of a healthy reference cohort.

While pulmonary complications are frequent with COVID-19, studies suggest that myocardial injury is common, in particular among those with chronic cardiovascular conditions and more severe COVID-19 presentations, and that its presence and magnitude is associated with worse outcomes.

Cardiologist and a large team of medical scientists at the Mayo Clinic (Rochester, MN, USA) conducted a multicenter, retrospective, observational, US-based study of COVID-19 patients undergoing high-sensitivity cardiac troponin T (hs-cTnT). The final study cohort included 367 COVID-19 patients in whom at least one hs-cTnT was obtained, amongst which 46% were identified to have myocardial injury based on hs-cTnT concentrations above the sex-specific 99th percentiles. The mean ± SD age of the cohort was 61 ±17 years and most patients presented through the Emergency Department (83%).

The hs-cTnT was measured with the Elecsys Troponin T Gen 5 STAT (Roche Diagnostics, Indianapolis, IN, USA). The lowest reportable clinical value is the <6 ng/L limit of quantification (LoQ). Sex-specific 99th percentiles URLs of 10 ng/L for women and 15 ng/L for men were used. Patients with suspected MI are evaluated using a 0/2 hour hs-cTnT protocol that uses sex-specific 99th percentile URLs to rule-in and rule-out myocardial injury and an absolute delta (serial change) of ≥10 ng/L to identify patients with acute injury. MI is diagnosed when there is objective evidence of myocardial ischemia.

The team reported that among 367 COVID-19 patients undergoing hs-cTnT, myocardial injury was identified in 46%. They had a higher risk for mortality (20% versus 12%), unadjusted hazard ratio (HR) of 4.44 and major adverse events (35% versus 11%). The hs-cTnT results were independent predictors of major adverse events. Most (95%) increases were due to myocardial injury, with 5% classified as type 1 or 2 myocardial infarction. A single hs-cTnT <6 ng/L identified 26% of patients without mortality, with a 94.9% (negative predictive value and 93.1% sensitivity for major adverse events in those presenting to the ED.

The authors concluded that myocardial injury is frequent and prognostic in COVID-19. While most hs-cTnT increases are modest and due to myocardial injury, they have important prognostic implications. A single hs-cTnT <6 ng/L at presentation may facilitate the identification of patients with a favorable prognosis. The study was published in the August 2021 issue of the journal Clinical Chemistry.

Related Links:
Mayo Clinic
Roche Diagnostics


Gold Supplier
Nucleic Acid Extraction System
SMPE-960
New
SARS-CoV-2 Antigen Rapid Test
Flowflex SARS-CoV-2 Antigen Rapid Test (Nasal/Saliva)
New
Gold Supplier
Liquid Handling Workstation
AdvanSure E3 SYSTEM
New
Urea Breath Test System for H. Pylori
BreathID Hp Lab

Print article

Channels

Pathology

view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more

Industry

view channel
Illustration

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.